Targets › RSV
9 programs from 7 companies in 18 trials: 13 Phase 1, 4 Phase 2, 1 Phase 3; Infectious disease, Vaccines, Respiratory; next expected readout Dec 2026.
Open in Phaseline: the race on RSV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| MAXVAX Biotechnology Limited Liability Company | Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells), low dose Recombinant RSV vaccine | RSV | Phase 3 | Respiratory Syncytial Virus (RSV); Respiratory Syncytial Virus Infections | Feb 2027 |
| Enanta Pharmaceuticals | Zelicapavir RSV non-fusion replication inhibitor | RSV | Phase 2 | RSV Infection; RSV | Dec 2026 |
| GSK | Adjuvanted RSVPreF3 vaccine RSV PreF3 protein subunit vaccine with adjuvant | RSV | Phase 2 | Respiratory Syncytial Virus Infections | Jan 2027 |
| Shenzhen Shenxin Biotechnology | Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) Bivalent mRNA vaccine targeting respiratory syncytial virus | RSV | Phase 2 | Respiratory Syncytial Virus (RSV) Infection; Respiratory Syncytial Virus Infections | Apr 2027 |
| Sanofi | Investigational hMPV/RSV vaccine mRNA vaccine encapsulated in lipid nanoparticle targeting hMPV and RSV | HMPV, RSV | Phase 1 | Human Metapneumovirus Immunization | Jan 2027 |
| ModernaTX | mRNA-1365 (Profile 2) mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) | RSV, HMPV | Phase 1 | Respiratory Syncytial Virus (RSV); Respiratory Syncytial Virus | Jul 2027 |
| AstraZeneca | AZD6489 RSV recombinant prefusion F protein virus-like particle (VLP) vaccine | RSV | Phase 1 | RSV Respiratory Syncytial Virus | Aug 2027 |
| Sanofi | RSV + HMPV Candidate Vaccine Live attenuated or recombinant viral vaccine against respiratory syncytial virus and human | RSV, HMPV | Phase 1 | Respiratory Syncytial Virus Immunization | May 2028 |
| ModernaTX | mRNA-1345 mRNA vaccine targeting respiratory syncytial virus (RSV) | RSV | Phase 1 | Respiratory Syncytial Virus | Aug 2029 |
Respiratory Syncytial Virus (RSV) (4) Human Metapneumovirus Immunization (4) Respiratory Syncytial Virus Infections (3) Respiratory Syncytial Virus (2) RSV Respiratory Syncytial Virus (1) Respiratory Syncytial Virus Immunization (1) RSV Infection (1) RSV (1) Respiratory Syncytial Virus (RSV) Infection (1)
other (6), mixed (2), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.